Asthma inhaler cost effectiveness
Pro Research Analysisby 
Searched over 200M research papers
Cost-Effectiveness of Triple Inhaler Therapy for Moderate-to-Severe Asthma
Several studies have shown that single-inhaler triple therapy, which combines an inhaled corticosteroid (ICS), a long-acting beta-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), is a cost-effective option for patients with uncontrolled moderate-to-severe asthma. In Canada, high-dose indacaterol/glycopyrronium/mometasone (IND/GLY/MF) was found to be both less costly and more effective than high-dose salmeterol/fluticasone (SAL/FLU) with or without tiotropium, resulting in lower overall costs and higher quality-adjusted life-years (QALYs) for patients . Similarly, in England, single-inhaler extrafine beclometasone/formoterol/glycopyrronium (BDP/FF/G) was cost-effective compared to dual therapy and even dominant (cheaper and more effective) compared to dual therapy plus tiotropium . In Colombia, triple therapy also showed a significant gain in QALYs at a low incremental cost, making it a cost-effective alternative before considering more expensive treatments like biologics .
Cost-Effectiveness of Inhaled Corticosteroids (ICS) in Mild-to-Moderate Asthma
For adults with mild-to-moderate asthma, adding inhaled corticosteroids to as-needed reliever therapy increases health care costs but also improves quality of life and reduces exacerbations and hospitalizations. The incremental cost per QALY gained is considered reasonable, and ICS use reduces acute exacerbations and hospitalizations by about one-third, making it a valuable investment in asthma management .
Comparing Inhaler Devices: MDIs, BAIs, and DPIs
The choice of inhaler device can impact both effectiveness and cost. Real-world studies show that dry powder inhalers (DPIs) and breath-actuated inhalers (BAIs) are generally more effective but also more costly than traditional metered-dose inhalers (MDIs). The incremental cost-effectiveness ratio for DPIs is higher, but they may offer better asthma control for some patients. The selection of inhaler should consider not just the device cost but also the potential for improved health outcomes and reduced resource use . Over longer periods, BAIs may become more cost-effective, especially as device prices and reimbursement policies change .
Digital Inhaler Technologies and Adherence
Digital inhalers, which monitor usage and provide feedback, have been shown to improve medication adherence and reduce the need for expensive add-on therapies like biologics. Studies indicate that digital inhaler interventions can lead to significant long-term cost savings by optimizing adherence and inhaler technique, resulting in fewer exacerbations and lower overall health care costs 56.
Cost-Effectiveness in Pediatric Emergency Care
In pediatric emergency departments, using MDIs with spacers instead of nebulizers for delivering bronchodilators in mild-to-moderate asthma exacerbations is both more effective and less costly. This approach can save hospitals money and reduce the burden on families and the health care system .
Over-the-Counter Inhalers for Mild Asthma
For underinsured adults in the United States, over-the-counter (OTC) as-needed budesonide-formoterol inhalers are more cost-effective and safer than OTC inhaled epinephrine. Budesonide-formoterol provides better asthma control, fewer severe exacerbations, and lower risk of asthma-related death, while also being cost-saving over a patient’s lifetime .
Conclusion
Asthma inhaler cost-effectiveness depends on the type of therapy, device, and patient population. Triple inhaler therapies are consistently cost-effective for moderate-to-severe asthma, while ICS use in mild-to-moderate asthma offers good value. Device choice and digital adherence technologies can further improve outcomes and reduce costs. For both adults and children, optimizing inhaler strategies can lead to better asthma control and significant health care savings 1234+6 MORE.
Sources and full results
Most relevant research papers on this topic
Cost-effectiveness of budesonide-formoterol versus inhaled epinephrine in United States adults with mild asthma.
OTC as-needed budesonide-formoterol for treating mild asthma in underinsured adults without HCP management improves asthma outcomes, prevents fatalities, and is cost-saving.
DOI